INVESTIGADORES
PASTORE valentina
artículos
Título:
EXPLORING THE ANTINOCICEPTIVE AND ANTIDEPRESSANT POTENTIAL OF 3,3-DIBROMOFLAVANONE: A NOVEL THERAPEUTIC CANDIDATE FOR PAIN MANAGEMENT WITH IMPROVED SAFETY PROFILE OVER MORPHINE
Autor/es:
NATALIA COLETTIS; JOSEFINA HIGGS; CRISTINA WASOWSKI; VALENTINA PASTORE; MARIEL MARDER.
Revista:
MEDICINA (BUENOS AIRES)
Editorial:
MEDICINA (BUENOS AIRES)
Referencias:
Lugar: Buenos Aires; Año: 2023
ISSN:
0025-7680
Resumen:
In the search for lead compounds with reduced side effects compared to opioids, the synthetic phytochemical 3,3-dibromoflavanone (3,3-DBF) emerged as a promising pain management candidate. 3,3-DBF displayed dose-dependent antinociceptive activity mediated by the µ-opioid receptor in central and peripheral pathways. Unlike morphine (MOR), chronic 3,3-DBF administration demonstrated antinociceptive effects without inducing tolerance, impacting locomotor activity, motor coordination, or causing constipation. This study aimed to explore 3,3-DBF effects in mice, focusing on dependence and depression, a typical pain comorbidity.The dependence effect was examined in mice divided into three group treatments, receiving 3,3-DBF, MOR, or vehicle twice daily for three consecutive days, with doses doubling daily to reach 60 mg/kg (MOR) and 100 mg/kg (3,3-DBF). On day four, half of each group treatment received either naltrexone (1 mg/kg), to induce withdrawal syndrome, or saline as a control. Withdrawal signs induced by 3,3-DBF were assessed using the Gellert-Holtzman scale. Two-way ANOVA followed by Dunnet indicated 3,3-DBF didn't elicit withdrawal signs (P>0.05) comparable to MOR (P
